BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 36872366)

  • 1. Erianin suppresses constitutive activation of MAPK signaling pathway by inhibition of CRAF and MEK1/2.
    Wang P; Jia X; Lu B; Huang H; Liu J; Liu X; Wu Q; Hu Y; Li P; Wei H; Liu T; Zhao D; Zhang L; Tian X; Jiang Y; Qiao Y; Nie W; Ma X; Bai R; Peng C; Dong Z; Liu K
    Signal Transduct Target Ther; 2023 Mar; 8(1):96. PubMed ID: 36872366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting oncogenic Raf protein-serine/threonine kinases in human cancers.
    Roskoski R
    Pharmacol Res; 2018 Sep; 135():239-258. PubMed ID: 30118796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.
    Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C
    Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations.
    Ahronian LG; Sennott EM; Van Allen EM; Wagle N; Kwak EL; Faris JE; Godfrey JT; Nishimura K; Lynch KD; Mermel CH; Lockerman EL; Kalsy A; Gurski JM; Bahl S; Anderka K; Green LM; Lennon NJ; Huynh TG; Mino-Kenudson M; Getz G; Dias-Santagata D; Iafrate AJ; Engelman JA; Garraway LA; Corcoran RB
    Cancer Discov; 2015 Apr; 5(4):358-67. PubMed ID: 25673644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors.
    Whittaker SR; Cowley GS; Wagner S; Luo F; Root DE; Garraway LA
    Mol Cancer Ther; 2015 Dec; 14(12):2700-11. PubMed ID: 26351322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RAF-MEK-ERK pathway in cancer evolution and treatment.
    Ullah R; Yin Q; Snell AH; Wan L
    Semin Cancer Biol; 2022 Oct; 85():123-154. PubMed ID: 33992782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations.
    Smalley KS; Xiao M; Villanueva J; Nguyen TK; Flaherty KT; Letrero R; Van Belle P; Elder DE; Wang Y; Nathanson KL; Herlyn M
    Oncogene; 2009 Jan; 28(1):85-94. PubMed ID: 18794803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumors.
    Merchant M; Moffat J; Schaefer G; Chan J; Wang X; Orr C; Cheng J; Hunsaker T; Shao L; Wang SJ; Wagle MC; Lin E; Haverty PM; Shahidi-Latham S; Ngu H; Solon M; Eastham-Anderson J; Koeppen H; Huang SA; Schwarz J; Belvin M; Kirouac D; Junttila MR
    PLoS One; 2017; 12(10):e0185862. PubMed ID: 28982154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.
    Poulikakos PI; Zhang C; Bollag G; Shokat KM; Rosen N
    Nature; 2010 Mar; 464(7287):427-30. PubMed ID: 20179705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allosteric Kinase Inhibitors Reshape MEK1 Kinase Activity Conformations in Cells and In Silico.
    Fleischmann J; Feichtner A; DeFalco L; Kugler V; Schwaighofer S; Huber RG; Stefan E
    Biomolecules; 2021 Mar; 11(4):. PubMed ID: 33808483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of a novel pan-RAF inhibitor with potent anti-tumor activity in preclinical models of BRAF
    Hong SP; Ahn SK
    Life Sci; 2017 Aug; 183():37-44. PubMed ID: 28645859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanism of RAF isoform switching induced by oncogenic RAS in melanoma.
    Dumaz N
    Small GTPases; 2011 Sep; 2(5):289-292. PubMed ID: 22292133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors.
    Lito P; Saborowski A; Yue J; Solomon M; Joseph E; Gadal S; Saborowski M; Kastenhuber E; Fellmann C; Ohara K; Morikami K; Miura T; Lukacs C; Ishii N; Lowe S; Rosen N
    Cancer Cell; 2014 May; 25(5):697-710. PubMed ID: 24746704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.
    Emery CM; Monaco KA; Wang P; Balak M; Freeman A; Meltzer J; Delach SM; Rakiec D; Ruddy DA; Korn JM; Haling J; Acker MG; Caponigro G
    Mol Cancer Res; 2017 Oct; 15(10):1431-1444. PubMed ID: 28655712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dimerization of the kinase ARAF promotes MAPK pathway activation and cell migration.
    Mooz J; Oberoi-Khanuja TK; Harms GS; Wang W; Jaiswal BS; Seshagiri S; Tikkanen R; Rajalingam K
    Sci Signal; 2014 Aug; 7(337):ra73. PubMed ID: 25097033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel phosphorylation site involved in dissociating RAF kinase from the scaffolding protein 14-3-3 and disrupting RAF dimerization.
    Yu A; Nguyen DH; Nguyen TJ; Wang Z
    J Biol Chem; 2023 Oct; 299(10):105188. PubMed ID: 37625591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells.
    Jenkins MH; Croteau W; Mullins DW; Brinckerhoff CE
    Matrix Biol; 2015 Oct; 48():66-77. PubMed ID: 25989506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of the CRAF/prohibitin interaction reverses CRAF-dependent resistance to vemurafenib.
    Doudican NA; Orlow SJ
    Oncogene; 2017 Jan; 36(3):423-428. PubMed ID: 27321184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinct dependencies on receptor tyrosine kinases in the regulation of MAPK signaling between BRAF V600E and non-V600E mutant lung cancers.
    Kotani H; Adachi Y; Kitai H; Tomida S; Bando H; Faber AC; Yoshino T; Voon DC; Yano S; Ebi H
    Oncogene; 2018 Mar; 37(13):1775-1787. PubMed ID: 29348459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib.
    Corcoran RB; Ebi H; Turke AB; Coffee EM; Nishino M; Cogdill AP; Brown RD; Della Pelle P; Dias-Santagata D; Hung KE; Flaherty KT; Piris A; Wargo JA; Settleman J; Mino-Kenudson M; Engelman JA
    Cancer Discov; 2012 Mar; 2(3):227-35. PubMed ID: 22448344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.